Pfizer Global Medical Grants (GMG) RFP: Multidisciplinary Gene Therapy Education – Recombinant Adeno-Associated Virus (rAAV)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Thursday 15th, September 2022
External Deadline: Tuesday 20th, September 2022
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct, of the independent program.
Geographic Scope: Global
Clinical Area: Gene Therapy – Rare Disease
Link to full RFP: Multidisciplinary Gene Therapy Education – Recombinant Adeno-Associated Virus (rAAV)
Application Due Date: September 20, 2022
Specific Area of Interest: Through this RFP we seek to support educational initiatives that focus on one or both of the following:
- Improving the medical and scientific understanding of recombinant adeno-associated virus (rAAV) gene therapy to help prepare multidisciplinary teams for the integration of rAAV gene therapy into the treatment armamentarium of eligible patients with a Rare Disease
Advancing the preparedness of gene therapy centers with institutional and/or multidisciplinary team training to execute clinical and operational best practices (e.g., SOPs and workflows) to optimize the quality of care for patients who are eligible for available recombinant adeno-associated virus (rAAV) gene therapies.
Refer to complete details in the full RFP documents. If you have questions regarding these RFPs, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).